ArticleNeurology and therapy2026
Comparative Efficacy of Rozanolixizumab with Efgartigimod or Intravenous Immunoglobulin in Generalized Myasthenia Gravis Using Matching Adjusted Indirect Comparisons.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGeneralized myasthenia gravis (gMG) is a rare autoimmune disorder affecting neuromuscular transmission. New targeted treatments including FcRn antagonists have emerged, but direct comparative evidence is lacking. This study aimed to compare the efficacy of rozanolixizumab with efgartigimod or intravenous immunoglobulin (IVIg) using matching-adjusted indirect comparisons (MAICs).
methodsPhase 3 studies of rozanolixizumab and efgartigimod were identified through a literature review. MAICs compared rozanolixizumab (7 mg/kg and 10 mg/kg) with efgartigimod 10 mg/kg IV and IVIg. Anchored comparisons (rozanolixizumab vs. efgartigimod) and unanchored comparisons (rozanolixizumab vs. IVIg) were used. Propensity score weighting balanced covariates between trial populations. Continuous outcomes were analysed using linear regression, and logistic regression for dichotomous outcomes. Treatment effects were presented as mean differences or odds ratios with 95% confidence intervals (CI). Scenario analyses were performed.
resultsRozanolixizumab efficacy was comparable to efgartigimod except for Quantitative Myasthenia Gravis (QMG) and Myasthenia Gravis Composite (MGC) scores at 6 weeks which were significantly in favour of rozanolixizumab 10 mg/kg (QMG mean difference - 2.80; 95% CI - 5.00, - 0.60; MGC mean difference - 3.89; - 6.72, - 1.05). Both rozanolixizumab doses significantly improved QMG scores from baseline at 2 weeks vs. IVIg (7 mg/kg: - 1.95; - 3.79, - 0.11; 10 mg/kg: - 1.99; - 3.71, - 0.26) and 4 weeks (7 mg/kg: - 3.40; - 5.23, - 1.56; 10 mg/kg: - 3.99; - 5.81, - 2.17). QMG responders at 2 weeks were not significantly different for rozanolixizumab vs. IVIg.
conclusionsWithout direct comparative evidence, these analyses provide additional context to inform treatment decisions for the management of gMG. These analyses suggest that FcRn inhibitors represent important targeted treatment options for gMG.
Indexed as
Identifiers
42786373What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.